Cencora

Cencora, Inc. is a United States-based pharmaceutical distribution and healthcare-services company headquartered in Conshohocken, Pennsylvania. The company operates primarily as an intermediary between pharmaceutical and biopharmaceutical manufacturers and the organizations that provide medicines to patients. Its customers and partners include hospitals and health systems, retail and independent pharmacies, specialty practices, physicians, clinics, long-term-care providers, mail-order pharmacies, pharmaceutical manufacturers, and animal-health businesses. The company was created in 2001 through the combination of AmeriSource Health Corporation and Bergen Brunswig Corporation. David Yost, who had led AmeriSource, continued as chief executive after the merger. The resulting business developed into one of the largest pharmaceutical wholesalers in the United States, distributing branded, generic, specialty, over-the-counter, and home-health products. Its distribution activities have been complemented by consulting, patient-support, logistics, clinical-trial, and specialty-care services. Before 2023, the company was widely known as AmerisourceBergen. On August 30, 2023, it adopted the Cencora name and began trading under the COR ticker on the New York Stock Exchange. The rebrand was intended to present the company as more than a traditional wholesaler, emphasizing its role in biopharmaceutical commercialization, specialty therapies, patient access, and healthcare logistics. The historical AmerisourceBergen name remains relevant in descriptions of the company's earlier operations, legal proceedings, acquisitions, and brands. Cencora's principal business areas have included pharmaceutical distribution, specialty distribution, manufacturer services, consulting, and temperature-controlled and time-sensitive logistics. World Courier, acquired in 2012, expanded the company's capabilities in global biopharmaceutical transportation and clinical-trial logistics. Other acquisitions strengthened its positions in veterinary pharmaceuticals, compounding services, national drug wholesaling, European distribution, and specialty healthcare. The company has also operated or sponsored healthcare-related brands and programs, including Good Neighbor Pharmacy, a cooperative network of independently owned pharmacies. The company distributes generic and branded prescription medicines, specialty and biologic therapies, over-the-counter healthcare products, and home-health supplies and equipment. Through its services businesses, it supports manufacturers with commercialization, market access, patient assistance, reimbursement, adherence, and related programs. It also provides distribution and services for specialty practices and alternate-care sites, where treatment may require cold-chain handling, complex reimbursement support, or direct coordination with patients and providers. Cencora has been involved in major public-health and regulatory issues affecting pharmaceutical distribution. In 2020, the United States government worked with the company and Gilead Sciences to allocate remdesivir shipments to American hospitals during the COVID-19 pandemic. The company has also faced extensive litigation concerning opioid distribution and a federal enforcement matter involving the repackaging and sale of adulterated or unapproved injectable medicines. These matters have shaped public discussion about distributor oversight, controlled-substance monitoring, product integrity, and the responsibilities of pharmaceutical intermediaries. Cencora remains an active, publicly traded healthcare company with operations extending beyond the United States. Its current positioning centers on improving medicine access and supply-chain reliability while helping manufacturers and healthcare providers manage increasingly specialized therapies. The business is distinguished from drug manufacturers because its core role is distribution and services rather than the discovery…

Cencora traces its corporate origins to the 2001 merger of AmeriSource Health Corporation and Bergen Brunswig Corporation. The combined company adopted the AmerisourceBergen name and retained David Yost, the former head of AmeriSource, as chief executive. Its initial business was centered on pharmaceutical wholesaling: purchasing medicines and healthcare products from manufacturers and supplying them to hospitals, pharmacies, physicians, clinics, long-term-care providers, and other care sites. During the 2000s and 2010s, AmerisourceBergen broadened its activities beyond conventional wholesale distribution. It developed specialty distribution and manufacturer-services businesses aimed at complex medicines, oncology products, biologics, and therapies requiring additional reimbursement or patient-support coordination. The company also built or acquired capabilities in packaging, consulting, clinical-trial support, and healthcare logistics. A major expansion came in 2012 with the acquisition of World Courier Group. World Courier added a global network specializing in temperature-sensitive, time-critical, and clinical-trial shipments for biopharmaceutical companies. AmerisourceBergen subsequently operated through several principal business areas, including its United States drug-distribution operation, specialty distribution, consulting and manufacturer services, and World Courier. Other acquisitions added veterinary distribution through MWI Veterinary, compounding through PharMEDium, and national wholesale scale through H. D. Smith. In 2021, AmerisourceBergen acquired Alliance Healthcare from Walgreens Boots Alliance. The deal extended the company's distribution footprint in European markets and strengthened its position as an international healthcare supply-chain operator. The company also maintained relationships with community pharmacies through Good Neighbor Pharmacy, a branded cooperative network for independently owned pharmacies. The business became involved in several prominent legal and regulatory controversies. Federal authorities pursued allegations concerning the repackaging and distribution of injectable drugs through subsidiaries and related billing and marketing practices. The company agreed to substantial civil and criminal resolutions in 2018. AmerisourceBergen was also among the pharmaceutical distributors sued by states, local governments, and the federal government over alleged failures in opioid monitoring and controls. In 2022, it joined other major distributors in a broad settlement framework covering much of the United States opioid litigation, while not admitting wrongdoing. During the COVID-19 pandemic, AmerisourceBergen participated in the United States distribution system for remdesivir. Under an arrangement involving the Department of Health and Human Services and Gilead Sciences, the company helped allocate supplies to hospitals in coordination with government authorities and states. This episode illustrated the strategic role of large distributors in allocating scarce medicines during public-health emergencies. On August 30, 2023, AmerisourceBergen changed its corporate name to Cencora and began trading under the COR symbol. The rebrand reflected a strategic effort to associate the company with a broader set of services linking manufacturers, providers, and patients rather than with wholesale distribution alone. In 2024, Cencora disclosed a cyber incident involving exposure of patient information. In 2025, it acquired an 85 percent interest in Retina Consultants of America, extending its specialty-care activities into a physician-platform investment. Cencora's present business remains organized around the movement and support of medicines. Its distribution operations handle branded, generic, specialty, over-the-counter, and home-health products, while its services businesses support commercialization, market access, patient assistance, reimbursement, clinical research, and specialized logistics. The company is therefore best understood as a pharmaceutical distribution and healthcare-services enterprise, not as a conventional research-based drug manufacturer.

1. 2025Retina Consultants of America investment

   Cencora acquired an 85 percent stake in Retina Consultants of America.

   Source
2. 2023Corporate rebrand to Cencora

   AmerisourceBergen adopted the Cencora name and began trading as COR on the New York Stock Exchange.

   Source
3. 2021Alliance Healthcare acquisition

   The company acquired Alliance Healthcare from Walgreens Boots Alliance.

   Source
4. 2018H. D. Smith acquisition

   AmerisourceBergen acquired H. D. Smith to expand its United States wholesale network.

   Source
5. 2015Expansion into veterinary and compounding services

   The company acquired MWI Veterinary and PharMEDium.

   Source
6. 2012World Courier acquisition

   AmerisourceBergen acquired World Courier, adding global specialty, clinical-trial, and temperature-controlled logistics.

   Source
7. 2001Formation through merger

   AmeriSource Health Corporation and Bergen Brunswig Corporation merged to form AmerisourceBergen.

   Source

A healthcare supply-chain and services partner connecting pharmaceutical manufacturers with providers and patients, with particular emphasis on specialty medicines, biopharmaceutical logistics, commercialization support, and access services.

• Pharmaceutical distributionDistribution2001

  Cencora distributes branded and generic prescription medicines to hospitals, health systems, pharmacies, physicians, clinics, mail-order facilities, long-term-care organizations, and other healthcare providers. The operation includes purchasing, warehousing, order fulfillment, and delivery across a large healthcare supply chain.

• Specialty pharmaceutical servicesSpecialty healthcare

  The specialty business supports products such as biologics, oncology therapies, and other complex medicines. Services may include specialty distribution, reimbursement coordination, patient support, access programs, and assistance to manufacturers and specialist providers.

• World CourierHealthcare logistics2012

  World Courier provides global logistics for biopharmaceutical products, clinical-trial materials, and other time-sensitive healthcare shipments. Its capabilities include specialized handling and temperature-controlled transportation for products whose quality depends on tightly managed supply conditions.

• Good Neighbor PharmacyPharmacy network

  Good Neighbor Pharmacy is a branded cooperative network associated with independently owned pharmacies. The network provides participating pharmacies with a common identity and business resources while allowing them to retain independent ownership and local operations.

• Home-health supplies and equipmentHome healthcare

  Cencora distributes healthcare supplies and equipment used outside hospitals, supporting home-care providers and other alternate-care settings alongside its pharmaceutical distribution activities.

• 2020United States remdesivir allocation program

  United States

  Cencora's predecessor AmerisourceBergen worked with the United States Department of Health and Human Services, state authorities, and Gilead Sciences to allocate remdesivir shipments to hospitals during the COVID-19 pandemic.

  Outcome. The arrangement supported nationwide hospital allocation of a scarce COVID-19 treatment during the emergency period.

  Source
• Good Neighbor Pharmacy network and ThoughtSpot

  United States

  The company sponsors Good Neighbor Pharmacy, an independent-pharmacy cooperative network, and its associated ThoughtSpot trade-show program.

  Outcome. The program provides a shared brand and commercial platform for participating independent pharmacies.

  Source

• 2025Acquisition of majority stake in Retina Consultants of AmericaM&A

  Cencora sought to expand its presence in specialty healthcare and physician-led care platforms.

  What changed. Cencora acquired an 85 percent interest in Retina Consultants of America.

  Aftermath. The transaction broadened Cencora's specialty-care activities beyond distribution and logistics.

  Reported transaction value. Approximately US$4.4 billion (January 2025)

  Source
• 2023Rebrand from AmerisourceBergen to CencoraStrategy

  The company had expanded from conventional pharmaceutical wholesaling into specialty distribution, manufacturer services, patient support, and global healthcare logistics.

  What changed. It changed its corporate name to Cencora and adopted COR as its New York Stock Exchange ticker.

  Aftermath. The new identity positioned the company as a broader healthcare-services and pharmaceutical-supply-chain partner.

  Source
• 2020Participation in remdesivir allocationOther

  Hospitals required coordinated access to remdesivir during the COVID-19 emergency.

  What changed. AmerisourceBergen distributed and allocated remdesivir shipments under a government and manufacturer arrangement.

  Aftermath. The arrangement helped channel available treatment supplies to hospitals across the United States.

  Source

• 2024Cyber incident involving patient informationControversy

  Cencora disclosed a cyber incident in which patient information was exposed.

  Source
• 2022Opioid distribution litigationControversy

  AmerisourceBergen faced lawsuits alleging that its distribution of prescription opioids contributed to the United States opioid crisis. It joined other distributors in a broad settlement framework while not admitting wrongdoing.

  Source
• 2018Repackaged injectable-drug enforcement caseControversy

  Federal authorities alleged that AmerisourceBergen subsidiaries repackaged injectable medicines, including pre-filled syringes, and engaged in related billing and marketing practices. The company entered civil and criminal resolutions and paid substantial penalties.

  Source

• 2025Cencora acquires majority stake in Retina Consultants of America

  Cencora acquired an 85 percent interest in Retina Consultants of America, expanding its specialty-care platform.

  M&A
  Source
• 2023AmerisourceBergen becomes Cencora

  The company changed its corporate name to Cencora and adopted COR as its New York Stock Exchange ticker.

  Leadership changeOther
  Source
• 2021AmerisourceBergen acquires Alliance Healthcare

  The transaction acquired Walgreens Boots Alliance's pharmaceutical distribution business in several European markets.

  M&A
  Source
• 2020AmerisourceBergen supports United States remdesivir distribution

  The company worked with government authorities and Gilead Sciences to allocate remdesivir shipments to hospitals during the COVID-19 emergency.

  Other
  Source
• 2018AmerisourceBergen acquires H. D. Smith

  The company acquired the privately held United States pharmaceutical wholesaler to expand national distribution capabilities.

  M&A
  Source
• 2015AmerisourceBergen acquires MWI Veterinary

  The transaction expanded the company's animal-health distribution business.

  M&A
  Source
• 2015AmerisourceBergen acquires PharMEDium

  The acquisition added a pharmaceutical compounding business to the company's portfolio.

  M&A
  Source
• 2012AmerisourceBergen acquires World Courier

  The acquisition expanded the company into global biopharmaceutical transportation and specialty logistics.

  M&A
  Source
• 2001AmeriSource and Bergen Brunswig merge to form AmerisourceBergen

  The combination created the pharmaceutical distribution company that later became Cencora.

  M&A
  Source

1. Cencora
2. Cencora corporate website